论文部分内容阅读
目的观察探究异甘草酸镁注射液治疗重症肝炎的临床疗效。方法重症肝炎的患者80例,随机分成两组,各40例,对照组给予常规治疗,试验组在常规治疗基础上给予异甘草酸镁注射液治疗,比较两组的临床疗效。结果两组患者治疗6周后的血清总胆红素(Tbil),谷丙转氨酶(ALT),谷草转氨酶(AST),凝血酶原时间(PT)等指标较治疗前均明显降低,ALB较治疗前明显升高,差异有统计学意义(P<0.05)。试验组患者治疗6周后的Tbil明显低于对照组患者治疗6周后的Tbil检测结果 (P<0.05)。试验组患者的治疗2、4、6周后HBV-DNA转阴率以及治疗6周后HbeAg/抗-Hbe转换率均明显高于对照组患者,差异有统计学意义(P<0.05)。结论异甘草酸镁注射液治疗重症肝炎效果良好,可以降低血清总胆红素,谷草转氨酶,谷丙转氨酶水平,改善肝功能,阻止疾病的发展进程,建议临床上广泛使用异甘草酸镁注射液治疗重症肝炎。
Objective To investigate the clinical efficacy of magnesium isrimazole injection in the treatment of severe hepatitis. Methods Eighty patients with severe hepatitis were randomly divided into two groups (n = 40 in each group). The control group was given routine treatment. The experimental group was treated with magnesium glycyrrhizinate injection on the basis of conventional treatment. The clinical efficacy was compared between the two groups. Results The serum total bilirubin, ALT, AST and PT of the two groups were significantly lower than those before treatment Before significantly increased, the difference was statistically significant (P <0.05). The Tbil after 6 weeks of treatment in the test group was significantly lower than that of the control group after 6 weeks of treatment (P <0.05). The negative conversion rate of HBV-DNA and the conversion rate of HbeAg / anti-HBe after 6, 6 and 6 weeks in the test group were significantly higher than those in the control group (P <0.05). Conclusion Magnesium isrimazole injection is effective in treating severe hepatitis and can reduce serum total bilirubin, aspartate aminotransferase and glutamic-pyruvic transaminase levels, improve liver function and prevent the progression of the disease. It is recommended that magnesium isoglycyrrhizinate be used clinically to treat severe hepatitis.